Thus, radiotherapy, chemotherapy, or novel therapeutic strategies, such as inducible T cells co-stimulator (ICOS) agonist, NCT03829501, transforming growth factor-beta (TGF-β) inhibitor, NCT04429542, along with ICIs might unleash the silent anti-tumor immunity and further generate promising clinical prognosis by transforming the “cold” tumor into a “hot” tumor (2, 16, 41). The gene discussed is TGFB1; the disease is neoplasm.